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EPIGENETIC MODULATION IN BRAF-MUTATED METASTATIC COLORECTAL CANCER

Van Karlyle Morris, M.D.
Advisory Professor: Scott Kopetz, M.D., Ph.D.

Introduction: BRAF V600E mutations are associated with poor clinical outcomes for patients with
metastatic colorectal cancer (mCRC). Unlike other tumors with the same mutation, BRAF
inhibitors are ineffective as monotherapy. CRC tumors with BRAF V600E mutations are
associated with global hypermethylation, which may turn off tumor suppressor gene expression.
We studied demethylation in BRAF V600E mCRC to restore sensitivity to BRAF inhibitors.
Methods: Tumor databanks were investigated for genes differentially expressed according to
BRAF mutation status to identify genes which may be particularly susceptible to epigenetic
influence. Mouse xenograft models of BRAFV600E mCRC were treated with vemurafenib or
azacitidine, alone or in combination, to assess for changes in tumor size. Tumors and cell lines
exposed to azacitidine were analyzed for methylation status and for gene expression differences,
with particular emphasis on genes identified from the bioinformatics analysis.
Results: The addition of azacitidine did not restore sensitivity to vemurafenib in two xenograft
models of BRAF V600E mCRC. Genes critical to negative regulation of Wnt/β-catenin signaling
like RNF43 and Axin2 were significantly underexpressed in BRAF V600E mutant tumors when
compared to their wild-type counterparts. These genes were hypermethylated in the xenograft
models, which could be reversed with a demethylating agent.
Conclusions: The combination of a BRAF inhibitor and a demethylating agent does not appear to
have promising anti-tumor activity in preclinical models of BRAF V600E mCRC. Negative
regulators of Wnt/β-catenin signaling are influenced by hypermethylation. Future clinical trials
incorporating these genes as integral biomarkers should consider gene expression given the
relevant non-genomic alterations.
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Chapter I
INTRODUCTION
Colorectal Cancer in the United States: Colorectal cancer remains the second leading cause
of cancer mortality in the United States, with over 50,000 deaths expected in the United
States in 20161. Over this past several decades, survival for patients with metastatic disease
has increased due to the incorporation of increased surgical resection for patients with
oligometastatic disease in which few sites of distant metastases are present2-4. During this time,
however, there have not been many significant advances with regards to the use of systemic
agents in the management of metastatic colorectal cancer. Cytotoxic chemotherapies including
5-fluorouracil/oxaliplatin (FOLFOX) and 5-fluorouracil/irinotecan (FOLFIRI) remain the backbone
of treatment for metastatic disease5-8. The introduction of biological agents with monoclonal
antibodies which target VEGF (bevacizumab) and EGFR (e.g., cetuximab and panitumumab) do
improve survival outcomes further when used in combination with cytotoxic chemotherapy9-14.
Nonetheless, utilization of such biologic agents must incorporate clinical comorbidities and a
detailed knowledge of the specific genomic profiling of a given patient. For example, KRAS and
NRAS mutations, which occur in 45–55% of all patients with metastatic colorectal cancer15-17, are
contraindications to the administration of anti-–EGFR therapies, as these activating mutations
occur downstream of EGFR and are associated with inferior outcomes when used in patients
with RAS-mutated metastatic colorectal cancer9,18-21.

BRAF Mutations in Colorectal Cancer: Valine to glutamic acid substitutions (V600E) in the
BRAF oncogene occur independently of mutations in KRAS and NRAS22,23. Here, mutations in
the BRAF oncogene, found in approximately 5-10% of colorectal cancers22, cause constitutive
activation of the MAPK pathway24-26, which promotes tumor cell proliferation and anti-apoptotic
activity27. Along the MAPK signaling pathway, EGFR stimulation triggers activation not only of
1

the separate PI3K/Akt pathway but also of downstream RAS signaling proteins, including
KRAS and NRAS. Activation of these kinases results in subsequent phosphorylation and
increased activity of BRAF, which in turn activates MEK1 and MEK2. These proteins
subsequently are able to phosphorylate ERK1 and ERK2, which can then be translocated into
the nucleus in order to propagate the downstream affect her functions of the MAPK signaling
pathway28.

The BRAF V600E mutation is understood to be an adverse prognostic marker in patients with
metastatic colorectal cancer29. Patients with metastatic colorectal cancer who harbor this
mutation have inferior responses to standard cytotoxic chemotherapy agents relative to their
BRAF wild type counterparts30-33. In addition, BRAF V600E mutations are associated with unique
patterns of distant metastatic spread in patients with metastatic colorectal cancer, with higher
rates of involvement of peritoneum, brain, and bone30. For patients with BRAF V600E mutated
metastatic colorectal cancer, survival in the metastatic setting has been estimated at only 10
months, less than the 35 months expected in patients with metastatic BRAF wild-type
colorectal cancer (BRAFWT-colorectal cancer)30.

BRAF Inhibitors in the treatment of BRAF-mutated colorectal cancer: Unlike metastatic
melanoma, in which use of targeted inhibitors against the BRAF V600E kinase-like vemurafenib
and dabrafenib are associated with response rates as high as 50–60 percent34,35, success with
such agents in the treatment of metastatic colorectal cancer is far inferior. A phase I study of
vemurafenib noted only one partial response among 21 patients with metastatic BRAF-mutated
colorectal cancer, for a response rate of 5%36. A separate phase I/II study of a BRAF
inhibitor/MEK inhibitor reported similar modest efficacy, with a 12% partial response rate with
this combination37. These findings suggest that inhibition of the MAPK pathway alone does not
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adequately inhibit BRAF-mutated colorectal cancer tumor progression. Indeed, subsequent
preclinical work has shown that inhibition of BRAF by vemurafenib triggers compensatory
activity of EGFR38,39, which can bypass the inhibited BRAF to trigger downstream PI3K/Akt
and MAPK signaling. Concomitant inhibition of BRAF and EGFR leads to tumor regression in
preclinical xenograft models of BRAF mutated metastatic colorectal cancer not seen with
agents which block BRAF and/or EGFR alone. Translating these findings into the clinical
setting, early results from phase I/II clinical trials provide promising data that this approach
may have some success in the treatment of BRAF mutated metastatic colorectal cancer.
Nonetheless, resistance to target therapies invariably develops, and additional understanding
is required in order to deep in the antitumor response40. Understanding better the complex
biology underlying these tumors is essential in order to design improved treatment options for
this subset of patients.

Hypermethylation in BRAF-mutated colorectal cancer: Analysis of 239 tumors from The
Cancer Genome Atlas (TCGA) revealed that BRAF mutations occur predominantly within a
subpopulation of colorectal cancer that is characterized by a high genomic mutational burden,
a phenotype which is also observed with the presence of microsatellite instability41. In
colorectal cancer, microsatellite instability leads to deficient mismatch repair of DNA and can
be caused either by germline mutations in critical DNA mismatch repair proteins or by tumor
hypermethylation42,43. Here, promoter hypermethylation of the MLH1 gene leads to
downstream silencing of this gene and lack of activity of this critical DNA mismatch repair
protein.
Hypermethylation in colorectal cancer is associated with the CpG Island methylation
phenotype (CIMP). The vast majority (>90%) of BRAF-mutated colorectal cancer is CIMPpositive and features promoter regions of DNA enriched with cytosine-guanine (CpG)
dinucleotides44,45. Hypermethylation of tumor suppressor genes leads to gene silencing and
3

loss of cell cycle regulation, among other functions46,47. Without concurrent hypermethylated
genomes, BRAF-mutated colonocytes remain senescent48-50. Together, BRAF mutation and
hypermethylation comprise key molecular features of the “serrated adenoma” pathway to
colorectal cancer tumorigenesis51,52, which is named for the unique precursor lesion,
highlighting the key role of epigenetics in the pathogenesis of BRAF-mutated colorectal
cancer.

Wnt/β-catenin signaling in metastatic colorectal cancer: Alterations of the Wnt/-catenin
pathway are present in >90% of colorectal cancers41, and inhibition of this pathway remains
the "holy grail" for targeted therapies in this disease. Inactivating mutations in APC and
activating mutations in CTTNB1 account for the majority of these alterations53, and are
difficult to target pharmacologically54. The remaining fraction of colorectal cancer tumors are
wild-type (WT) for APC and CTTNB1 and often feature aberrancies in tumor cell surface
proteins like RNF43 and R-spondin (RSP0)55, which also lead to deregulated Wnt/-catenin
signaling56,57. These tumors derive predominantly from the sessile serrated adenoma
pathway and have a high proportion of BRAF mutations.

Wnt/ β -catenin signaling is important in the pathogenesis of colorectal cancer. Most
colorectal tumors are driven by aberrant Wnt signaling predominantly via APC and CTTNB1
mutations58,59. RNF43 mutations and RSPO fusions have been found in approximately 20%
of colorectal cancer tumors and are exclusive to APC and CTTNB1 mutations. The common
endpoint of these irregularities is nuclear translocation of β-catenin and upregulation of the Tcell factor transcriptional complex, promoting cell proliferation, anti-apoptotic behavior, and
the epithelial-to-mesenchymal phenotype60,61.

Preclinical work has suggested that targeted agents can dampen Wnt/-catenin signaling in
4

colorectal cancer models harboring RNF43 mutations or RSPO fusions62. However,
additional alterations, including epigenetic modulation, also activate Wnt signaling in a ligand
dependent manner in a subset of patients. Predictive biomarkers with available matched
targeted therapies against Wnt/-catenin signaling are needed in order to tailor novel agents
for patients with metastatic colorectal cancer.

5

CHAPTER II
METHODS
Xenograft Studies
Tumors were collected under an IRB-approved protocol from 2 patients with BRAF–mutated
metastatic colorectal cancer who were treated at M.D. Anderson for establishment of patientderived xenografts. The specimens were called “C0999” and “B1003” in order to provide names
for these models that included no personally identifiable patient information. These xenograft
tumors had been previously established by our group and were removed from storage at -80°
Celsius. The samples were thawed, and for each of the 2 models individually, the thawed tumor
was divided by scalpel at room temperature into 10 equal parts for an approximate volume of 4
x 4 x 4 mm. These smaller tumors were implanted subcutaneously into the right lateral flank of
10 individual female, NOD–SCID–gamma mice (purchased from Experimental Radiation
Oncology at M.D. Anderson).
Once it had been determined that the tumors were growing in the mice in which they had been
implanted, for each of the 2 different models, 6 mice were selected for further use once their
mean tumor volume was approximately 200 mm3. These 6 mice were randomized into 3 equal
arms (N=2 per arm) for initial treatment randomization. Here, an F1 generation was treated
intraperitoneally with placebo (phospho-buffered saline, Sigma Aldrich) or with 5–azacitidine
(Sigma Aldrich) at 2 different doses (0.25 mg/kg or 0.50 mg/kg). Intraperitoneal injections were
administered twice weekly. The F1 generation was utilized to allow for prolonged exposure a
demethylating agent prior to the experimental studies regarding a BRAF inhibitor in the F2
generation. Once these 6 tumors had reached a mean volume had reached a mean volume of
1500 mm3, the mice were sacrificed, and the tumors were harvested. Here, the tumors were
immediately divided using a scalpel into equal parts with approximate volumes of 4 x 4 x 4 mm.
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Tumors from the placebo/control mice in the previous F1 generation were implanted into 30
female NSG mice, and tumors from the 5–azacitidine treated mice were implanted into 30
different female NSG mice. Given that toxicities appeared to be similar/insignificant between the
mice in the F1 generation treated with azacitidine at doses of 0.25 mg/kg and 0.50 mg/kg, we
chose to continue with the tumors that had been exposed to azacitidine at a dose of 0.50 mg/kg
for the experimental studies as part of the F2 generation. We surmised that doing so would
optimize the exposure to a demethylating agent.
For the 2 sets of mice in the F2 generation which were treated with saline/placebo or
azacitidine, they continue to
receive twice-weekly
intraperitoneal injections until
the mean tumor size was
approximately 200 mm3. At that
time, mice were randomized in
a 1:1 fashion to receive or not to
receive concomitant
vemurafenib (see Figure 1 for
experimental flow). Vemurafenib was administered continuously as a chow at a dose of 417
mg/kg (Plexxikon/Scientific Diets), and control chow was provided by scientific diets as well.
This resulted in 4 different groups for analysis: untreated control, azacitidine only, vemurafenib
only, and azacitidine plus vemurafenib. Tumor volumes were measured twice-weekly and
calculated as the product of length2 x width/2, whereby length represents the longest axis of the
cross-sectional measurements of the particular tumor.
The primary endpoint here was tumor size after a five-week treatment period, and the primary
objective was to assess if the combination treatment resulted in smaller tumor size compared to
7

BRAF inhibitor treatment alone. For the primary comparison of tumor size at 5 weeks, we fit a
one-way ANOVA model to assess the difference among all four treatment groups in order to
derive the pairwise comparison results.
Bioinformatic Analysis
The CIMP-High status and the BRAF mutation data of the TCGA CRC samples were extracted
from the Memorial Sloan Kettering Cancer Center cBio portal (www.cbiopartal.org). The 36
corresponding CIMP-High samples were only retained in the RNAseq and Methylation datasets,
and BRAF mutation status was identified from the identified samples. Probes/genes were
queried from the 450,000 probes provided by the Illumina 27K methylation assay (Illumina, San
Diego, CA) to compare the BRAF wild-type and mutated populations. From these cases,
univariate analysis was performed to identify differentially expressed transcripts and
differentially methylated transcripts using t-test from the various probes of interest. The p-values
obtained by multiple t-tests were corrected with a false discovery rate using the beta-uniform
modeling (BUM) method. The same methodology strategy was performed using the available
data internally from the MD Anderson Integromics dataset. Again, RNAseq datasets were
analyzed according to BRAF mutant and BRAF wild-type specimens from patients with
colorectal cancer. Given the higher number of gene expression differences in various gene
probes for this dataset, we constructed a heat map to illustrate the differences in expression
patterns between these two populations of interest. Lists of genes with differential expression
were compared for the two independent analyses to provide a better validated identification of
genes which may be preferentially overexpressed (or underexpressed) in the BRAF-mutant
CRC population. The list of genes identified here was used as input into the IPA Ingenuity
BioProfiler list (www.ingenuity.com) to identify signaling pathways which may be most
influenced by the variations in gene expression for the selected genes of interest from the gene
expression analysis.
8

Methylation Profiling of Xenograft Tumors
We were interested as well in comparing the methylation profiling of the xenograft tumors
exposed or not exposed to azacitidine. Here, 15 xenograft tumors were analyzed – 7 control
tumors (4 from B1003 and 3 from C0999) and 8 experimental (3 from C0999 and 5 from
B1003). Frozen tumors stored at -80°C were thawed, and DNA was extracted and isolated
using a DNeasy Blood and Tissue kit (Qiagen, Valencia, CA). To check the overall methylation
pattern 10,000 highly variable probes were chosen from the Illumina 450k dataset. A next
generation heat map was generated using the highly variable probes for visualization.
To test whether or not azacitidine was successful in demethylating biologically relevant markers
for the presence of CIMP, three genes commonly hypermethylated in CRC tumors and
universally accepted as markers for the presence of CIMP-high status – CACNA1G, RUNX3,
and TIMP3 – were selected for further study. Here, mean methylation values (with associated
standard deviation) from the 5’-methylation probe for each of the individual genes were
calculated for the C0999 and B1003 tumors in the control and experimental/azacitidine arms.
Results were compared between control and experimental arms each of the two xenograft
models separately using a t-test in order to examine whether or not a difference in methylation
was noted for the tumors exposed to a demethylating agent.
Given that the Wnt/β-catenin signaling pathway had been demonstrated to be preferentially
affected for BRAF mutant versus wild-type tumors, various genes in this pathway were also
selected to assess for differences in methylation between the control and experimental/
azacitidine groups for the C0999 and B1003 models separately. Here, the following genes were
examined: APC2, AXIN1, AXIN2, CSNK1A1, CSNK1D, CSNK1E, CSNK1G1, CSNK1G2
CSNK1G3, DVL1, DVL2, DVL3, FZD1, FZD2, FZD3, FZD5, FZD6, FZD8, FZD9, FZD10,
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GSK3A, GSK3B, LRP1, LRP4, LRP5, LRP6, RNF43, and RSPO1. Results were compared
separately using a t-test for each of the given genes.
Gene Expression Profiling of BRAF-mutated CRC Models
To test further whether or not differences in gene expression were noted by the use of
azacitidine, we first extracted RNA (Qiagen RNeasy kit) from the same xenograft tumors which
had been analyzed for methylation for the C0999 and B1003 models. We were interested in
looking at the genes in which methylation differences had been noted between the control and
experimental (azacitidine-treated) arms in the xenograft studies to see if a corresponding
differential gene expression possibly affected by methylation was observed. Once isolated,
RNA was assessed by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR)
with probes specific for selected genes (APC2, AXIN1, AXIN2, CSNK1A1, CSNK1D, FZD9,
LRP1, LRP4, LRP5, RNF43). Mean expression levels for the selected genes were compared
between control tumors and experimental tumors for each of the two xenograft models. To look
at another data set, we had gene expression data generated from prior work with the
BRAFV600E CRC cell line HT29 treated with and without a demethylating agent. Cells were
treated for 14 days with or without azacitidine, and harvested for RNA to compare differences in
gene expression of selected genes. qRT-PCR was performed using probes from the same
genes in the Wnt/β-catenin signaling pathway as listed above. Differences between control and
experimental/treated cells were compared using a Student’s t-test.
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CHAPTER III
RESULTS
Xenograft Studies
Two different xenograft models of BRAF–mutated metastatic colorectal cancer – C0999 and
B1003 –were utilized for these experiments to assess whether or not the addition of azacitidine
to vemurafenib generates additional tumor regression. The results are seen in Figures 2 and 3.
In both experiments, 40 mice with established C0999 or B1003 BRAF–mutated metastatic
colorectal cancer xenografts were divided into 4 separate arms of 10 mice each. Mice were
treated as either untreated controls, or with vemurafenib, azacitidine, or the combination of
vemurafenib plus azacitidine. As seen in Figure 2, which represents the C0999 xenograft model,
the addition of vemurafenib, with or without azacitidine, generated a significant tumor
regression, with no
palpable tumor in either
arm, after 21 days of
treatment. However,
these tumors quickly
grew back with no
persistent response to
BRAF inhibition.
ANOVA analysis was used to demonstrate that a significant difference (P < .0001) in tumor
volume at day 28 was detected among before groups here. Specifically, although there were no
differences in tumor volume between control/azacitidine groups and vemurafenib/vemurafenib
plus azacitidine groups, there were differences between the 2 groups of mice which received
vemurafenib in the 2 groups of mice which did not receive vemurafenib.
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In Figure 3, the growth curves for the B1003 BRAF mutated metastatic colorectal cancer
xenograft model are shown, with individual arms for the untreated control, vemurafenib,
azacitidine, and
vemurafenib plus
azacitidine
combination
groups. Unlike
the prior
xenograft model,
ANOVA analysis
demonstrated no difference in tumor sizes between the four groups here (P=.66). For all
cohorts, the tumors demonstrated no regression noted for any of the mice treated with
experimental agents.
Collectively, for both xenograft models used here, C0999 and B1003, azacitidine did not cause
regression in mean tumor volume, independent of inhibition of BRAF with vemurafenib.
Bioinformatic Analysis of Gene Expression/Methylation Patterns
In order to perform differential expression analysis between the BRAF mutant and wild-type
sample groups in the RNAseq and methylation data of TCGA CRC dataset, we examined 226
samples with RNAseq and Methylation datasets both available. Of these 226 samples in this
dataset, 36 samples were in CIMP-High group. Sixteen were BRAF mutated, and twenty were
BRAF wild-type. With a False-Discovery Rate (FDR) threshold of 0.3, there were 55
significantly different transcripts in the RNAseq data (see Figure 4A) within the CIMP-high group
distinguished according to BRAF mutation status. Even with an FDR threshold of 0.3 there
were no significant probes in the methylation data (Figure 4B).
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We next turned to the Integromics cohort of patients at MD Anderson, a separate group of
patients independent from
the samples analyzed in the
TCGA, for whom genomic
(mutation) profiling, RNAseq
gene expression data, and
methylation data had already
been characterized. Here we
performed hierarchical
clustering using a heat map
generated by the gene expression data, and analyzed according to BRAF mutation status. As
seen in Figure 5, a clear difference in selected genes was noted for patients in this cohort
according to BRAF mutation status. There were 5954 genes which demonstrated differential
gene expression according to BRAF mutation status in the analysis of the RNAseq gene
expression data for the Integromics
cohort. CIMP high vs CIMP low
status was not available to select
only for the CIMP-high patients, as
had been done in the analysis of the
TCGA data. Genes of interest
which were preferentially
underexpressed for the BRAFmutated population relative to the
BRAF wild-type population in the
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Integromics cohort (with adjusted p-value to quantify the significance of difference) include
AXIN2 (2.8 x 10-13), FOXD1 (5.2 x 10-13), RNF43 (1.3 x 10-12), MLH1 (2.8 x 10-11), PTPRD (3.7 x
10-12), JUN (5.9 x 10-9), RBP2 (1.4 x 10-8), APC2 (4.9 x 10-8), and RNF44 (1.1 x 10-6).

Next, we were interested in identifying the union genes which were differentially expressed
according to BRAF mutation status for both the Integromics and TCGA separate cohorts. We
compared the 250 genes of highest significance of difference for each of the two datasets and
identified genes common to both lists. These genes are listed in Table 1 below, along with the
direction of change of gene expression (overexpressed or underexpressed) of the BRAFmutated patients relative to the BRAF wild-type population:

Gene

Relative expression in

Function of gene

BRAF-mutated cohorts
AXIN2

Underexpressed

Phosphorylates CTTNB1 in
preparation for degradation

EPDR1

Underexpressed

Cell-ECM adhesion

KHDRB53

Underexpressed

Inhibits cell proliferation

RNF43

Underexpressed

Negative regulator of
Wnt/beta-catenin signaling

MLH1

Underexpressed

Mismatch repair of DNA

RAB32

Underexpressed

Binds to regulatory unit of
PKA

TDGF1

Underexpressed

Cripto1:EGF signaling

KDSR

Overexpressed

Sphingosine/ceramide
synthesis
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Gene

Relative expression in

Function of gene

BRAF-mutated cohorts
JUN

Underexpressed

GTF21RD1

Underexpressed

Transcriptional regulator
under control of Rb

PTPRO

Underexpressed

Induced by Wnt signaling;
negative regulator of
Wnt/beta-catenin signaling

PLAGL2

Underexpressed

Inhibits differentiation to
generate stem cell phenotype;
upregulates Wnt signaling

RBP2

Underexpressed

Retinal-binding protein

TDGF3

Underexpressed

ID1

Underexpressed

Inhibitor of DNA binding

DDX27

Underexpressed

RNA helicase involved in
cellular growth/differentiation

HPSE

Overexpressed

Facilitates cell migration via
ECM degradation; cleaves
HSPGs

IHH

Underexpressed

Indian hedgehog

LM04

Overexpressed

Transcription factor for
oncogene activity

ZIC5

Overexpressed

DNA binding, activation of
transcription factors

CYP2B6

Underexpressed

Retinoic acid production
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Gene

Relative expression in

Function of gene

BRAF-mutated cohorts
FERMT1

Underexpressed

Links extracellular matrix to
cytoskeleton

NR1I2

Underexpressed

Binds CYP3A4 and RXRA

GPR56

Underexpressed

Cell adhesion; in melanoma,
overexpression inhibits
metastases

MOSC2

Overexpressed

GRAMD1A

Underexpressed

KDELR3

Overexpressed

TINAG

Underexpressed

SPATA2

Underexpressed

SEC22B

Overexpressed

Golgi: ER processing

Table 1: Genes preferentially expressed (direction of change listed in middle column) for
BRAF-mutated CRC tumors in the Integromics cohort and the TCGA cohorts, with
description of the functional relevance of selected genes in the third column.

With many genes here demonstrating differential gene expression among the BRAF mutated
and BRAF wild-type cohorts, we were next interested in understanding what signaling pathways
may be preferentially affected by the presence or absence of a mutated BRAF. We performed
an Ingenuity IPA pathway analysis incorporating the identified genes, common to both the
TCGA and Integromics data sets, with the results for the most significant signaling pathways
listed in Figure 6:
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One of the strongest links was in genes affecting “colorectal cancer metastasis signaling,” which
serves as a confirmatory positive control for the biological relevance of this analysis here. Other
pathways of interest included pathways involved in inflammation/immune activity (“role of
macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis,” “granulocyte adhesion
and degradation,” “natural killer cell signaling,” and “B cell receptor signaling”). Of great
interest, the Wnt/β-catenin signaling pathway was also associated with preferential activity in the
BRAF-mutated colorectal cancer cohorts per the results of this pathway analysis.

Methylation Profiling of Xenograft Tumors
Given that no significant differences in tumor volumes were noted in the xenograft studies with
the use of a demethylating agent, we next performed methylation profiling for the various tumors
treated with or without azaciditine to assess whether or not changes in methylation were
occurring. To check the overall methylation pattern 10,000 highly variable probes were chosen
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from the Illumina 450k dataset. The next generation heat map from this analysis is
demonstrated in Figure 7.

Clearly, for the C0999 and B1003 models alike, profiles for methylation are very similar. In this
figure, red represents an overall lower degree of methylation, whereas the whiter hue
represents a higher level of methylation. In the untreated controlled groups, for both xenograft
models, for the selected probes there is a methylation profiling which demonstrates clear higher
levels of methylation overall relative to the 2 groups (C0999 and B1003) which were exposed to
azacitidine. In addition, the individual xenograft tumors treated with azacitidine clustered
together between the individual models. In other words, all of the C0999 xenograft tumors that
were treated with azacitidine had a methylation profiling that was separate and distinct from the
B1003 xenograft tumors that were treated a demethylating agent. These results lend support to
the notion that azacitidine was indeed capable of performing his task in the xenograft tumors –
i.e., reversing methylation of specific genes. Therefore, it cannot be concluded that no

18

differences in tumor volumes were observed due to the lack of demethylation by azacitidine.
Instead, this drug was able to alter the overall methylation patterns within the given tumor.
We also looked at genes which are known to be under epigenetic regulation and, when
methylated, characterize the presence of CIMP–high status for a given tumor. Specifically, we
looked at the 3 genes CACNA1G, RUNX3, and TIMP3. As seen in Figure 8, for both xenograft
models, the addition of azacitidine resulted in a significantly lower degree of methylation in the
experimentally treated group when compared to the untreated controls. This provided additional
evidence to us that the administration of a demethylating agent resulted in changes in
methylation profiling and serves as a positive pharmacodynamics biomarker that azacitidine
was indeed performing its specified task in these studies (P< .005 for all six comparisons).

Methylation/gene expression analysis of Wnt/β-catenin targets
The Wnt/β-catenin signaling pathway was a pathway previously identified to show differential
gene expression for colorectal tumors according to the presence or absence of a BRAF
mutation. We next proposed to examine specific genes of interest in this pathway in order to
assess whether their expression may be affected by demethylation. Specifically, we compared
methylation levels between untreated control groups and their corresponding azacitidine groups
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for each of the two xenograft models for the following genes: Axin1, Axin2, APC2, CSNK1A1,
CSNK1G2, CSNK1D, FZD9, FZD1, LRP4, and LRP5. Statistically significant changes in
methylation (P<.05 for all) were noted with the addition of a demethylating agent, as seen in
Figure 9:

Here, methylation levels of genes like Axin2, CSNK1A1, Fzd9, Fzd1, and Lrp4 were reduced in
both models of BRAF-mutated metastatic colorectal cancer with the addition of azacitidine,
whereas higher methylation of Axin1 and APC2 were noted with the same intervention.
Comparison of Gene Expression Profiling of selected genes in the Wnt/β-catenin
signaling pathway for the Xenograft models of BRAF-mutated colorectal cancer
Given that we found significant differences between the various previously mentioned genes in
this signaling pathway, we next analyzed gene expression profiling on the xenograft tumors
individually and compared the mean values between the control groups and the azacitidine
groups to assess whether or not these changes in methylation correlated to matched changes in
gene expression profiling. Table 2 lists the magnitude of change (ratio) of the mean level of
gene expression by RNAseq for the azacitidine group relative to that of the untreated control
group. In all instances, a t-test was performed to compare the mean values the P value to
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compare for a difference between the untreated control and the experimental groups exceeded
0.05, and therefore none of the differences noted were statistically significant for these
experiments.
Here, the direction of change for CSNK1A1, CSNK1D, Fzd9, and Fzd1 were all increased,
which corresponded to the direction of change for the matched change in methylation noted by
the addition of azacitidine in the respective experiments, which was decreased. Therefore, the
methylation changes were biologically consistent with the changes in the gene expression.
Gene

C0999

B1003

Axin1

1.21

.93

Axin2

1.16

.76

APC2

4.02

1.22

CSNK1A1

1.07

1.34

CSNK1D

1.00

1.04

Fzd9

25.7

1.37

Fzd1

1.09

1.79

Lrp4

1.00

.73

Lrp5

1.12

.97

Table 2: Magnitude of change in mean gene expression of various genes in Wnt/βcatenin signaling upon addition of azacitidine.
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qRT-PCR Analysis of BRAF-mutated xenograft models
To investigate further whether or not there were differences in gene expression upon the
addition of azacitidine for the C0999 and B1003 models, we performed quantitative reversetranscriptase PCR (qRT-PCR) on frozen specimens of xenograft tumors in the untreated
controls and in the cohort exposed to azacitidine. Mean values (with standard error) are
demonstrated for each of these genes in Figure 10: Here, no significant changes in gene
expression according to qRT-PCR were noted in any of the genes assessed in this pathway
with the exception of RNF43 in the B1003 model, whose expression did increase upon
exposure to azacitidine. Interestingly, RNF43 was also the gene with the strongest association
with preferentially decreased expression in the gene expression profiling for the BRAF-mutated
colorectal tumors relative to the BRAF wild-type tumors.
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qRT-PCR Analysis of BRAF-mutated cell line models We also looked at the HT29 BRAF–
mutated colorectal cancer cell line for changes in methylation and in gene expression upon the
introduction of azacitidine. Here, we compared mean values for differences in methylation and
in gene expression for untreated controls versus cells treated with a demethylating agent using
qRT-PCR provided from an outside, publicly available data set.

Table 3 demonstrates the

magnitude of change in the ratio is for both methylation and corresponding gene expression in
mean is azacitidine: untreated control for each of the listed genes important in the signaling
pathway. Values with significant differences are listed, but otherwise only trends, but no
statistically significant differences, were observed upon the addition of azacitidine. Notably,
decreases in mean levels of methylation were observed for Fzd9 and Lrp4 with an associated
increase in gene expression upon addition of azacitidine. Increases in methylation were
likewise observed with Axin1 and Lrp5 with associated decrease in gene expression of these
genes. In addition, expression of the surface proteins RSPO2 and RSPO4 were observed upon
exposure to azacitidine, and neither of these genes were expressed at detectable levels by
qRT-PCR in the untreated control HT29 cells.
Gene

Methylation change

RNAseq change
(for azacitidine)

Axin1

↑

↓ (P=.04)

Axin2

↓

↑

APC2

↑

↑

CSNK1A1

↓

↓

CSNK1D

↓

↓

Fzd1

↓

↑ (P=.03)
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Gene

Methylation change

RNAseq change
(for azacitidine)

Fzd9

↓

↑

Lrp4

↓

↑ (P=.06)

Lrp5

↑

↓ (P=.04)

RNF43

↓

↓

RSPO2

↑ (0 -> detected)

RSPO 4

↑ (0 -> detected)

Table 3: Direction of change in mean methylation and gene expression of various genes
in Wnt/β-catenin signaling upon addition of azacitidine in HT29 BRAF-mutated colorectal
cells.
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CHAPTER IV
DISCUSSION
BRAF–mutated metastatic colorectal cancer represents a rare subset of the colorectal cancer
population with characteristic clinical and pathological features. Notably, these tumors are
associated with concomitant microsatellite instability and global hypermethylation. As patients
whose colorectal tumors harbor these BRAF V600E mutations demonstrate poor responses to
standard cytotoxic chemotherapy regimens and rapid clinical deterioration that lead to terrible
survival outcomes, new therapies are desperately needed in order to provide this group of
patients otherwise effective treatment. This proposal sought to address the role of
hypermethylation in these BRAF mutated colorectal tumors by a set seeing the role of a
demethylating agent in combination with a BRAF inhibitor and by identifying signaling
pathways/potentially targets which have the potential to be manipulated by demethylating
agents.
Azacitidine is a nucleoside analogue which forms covalent bonds with DNA methyltransferases
and inhibits further methylation of downstream nucleotides, thereby promoting an overall
demethylated state63. Demethylating agents have FDA–approval for clinical use in hematologic
disorders such as myelodysplastic syndrome. However, the clinical utility of azacitidine in solid
tumors is less understood. Preclinical studies have shown that brief exposure of epithelial tumor
cell lines to low doses of demethylating agents generates a sustained anti-tumor effect, even
against subpopulations of solid tumors not sensitive to standard chemotherapy64. These
findings provided us with the rationale to study lower doses of azacitidine over prolonged
treatment time with the goal of understanding whether or not demethylation can restore
sensitivity to BRAF inhibitors in preclinical models of colorectal cancer.
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We examined two xenograft models of BRAF mutated metastatic colorectal cancer to
investigate the interplay between BRAF inhibitors and demethylating agents. To our surprise,
the C0999 model showed sensitivity to single agent therapy with the BRAF inhibitor
vemurafenib. Here, after approximately 3 weeks, all tumors developed complete regression with
this therapy. Eventually, all tumors treated with the BRAF inhibitor develop resistance to this
therapy, and detailed analysis of these findings was performed and has been described
elsewhere (manuscript under review). Our conclusions, based on mutational profiling at the time
of acquired resistance, were that these tumors were dependent on continued MAPK signaling
as a means to propagate tumor growth. Regardless, in both the C0999 model and the B1003
model, the addition of azacitidine had no effect on treatment response/tumor volume either by
itself or in combination with vemurafenib.
Given these findings, we were interested in understanding whether or not these azacitidine was
even affecting methylation patterns at the low dose at which was being administered. To assess
this further, we performed genomic methylation profiling on the tumors in the control arms and in
the tumors treated with a demethylating agent. Clearly, differential methylation profiling was
seen in the tumors that were treated with azacitidine. Some of the methylation probes were
noted to be hypermethylated in the control tumors and then convert to a less methylated state
upon exposure to azacitidine, whereas other probes were noted to be more demethylated in the
control and become more methylated with the addition of azacitidine. Notably, many of the
latter cases happen to be probes that were assessing methylation within the bodies of genes of
interest (downstream from the 5’-promoter sequence). On the other hand, many of the probes
which were relatively more methylated in the control group were found on the 5’-promoter foci.
Previous work on the X-chromosome studying the relationship between epigenetic modulation
and gene expression has shown that, in genes which are actively express, an inverse
relationship exists in methylation patterns between the promoter sequence and gene body
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sequence65. In other words, decreased methylation at the promoter site with corresponding
relative hypermethylation at the gene body can be associated with higher levels of gene
expression. Alternatively, higher methylation levels in the promoter region with corresponding
lower methylation patterns in the gene body sequence can be associated with relatively lower
levels of gene expression. These patterns could explain why there were regions of both
hypermethylation and relative hypomethylation in the xenograft tumors randomized to the
control arm, which were reversed with use of a demethylating agent. As evident by our data,
methylation patterns were reversed by azacitidine. Despite the fact then that there was no
change in tumor volume with the addition of azacitidine, this drug was nonetheless
pharmacodynamically effective in reversing methylation patterns with the use of a lower dosed,
prolonged exposure to a demethylating agent treatment strategy.
Next, we were interested in identifying genes which may be preferentially affected by
methylation changes in the BRAF mutated colorectal cancer population relative to the BRAF
wild type counterparts. Based on gene expression characterization, genes like MLH1 were
preferentially under expressed in the BRAF mutated population. Decreased expression of this
gene is associated with deficient mismatch repair in colorectal cancer43,66, and, given that BRAF
mutations are likewise associated with microsatellite instability, this findings served as a positive
control that provided validation to our data within the correct clinical context for the biologic
understanding of colorectal cancer. Interestingly, two of the most significantly underexpressed
genes in the BRAF–mutated population were AXIN2 and RNF43. Both of these genes serve as
negative regulators of Wnt/β-catenin signaling, and, when not fully present, can be associated
with increased activity of this pathway which is seminally important in the pathogenesis of
colorectal cancer. RNF43 mutations often occur mutually exclusively to APC mutations55, and
appear to co-occur more commonly with BRAF mutations (unpublished data estimated RNF43
mutations present in 64% of BRAF mutated colorectal tumors). This protein is found at the
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surface of the tumor cell and functions to downregulate the presence of the Wnt ligand receptor
Frizzled (Fzd). Similarly, AXIN2 is also important in modulating activity of the Wnt/β-catenin
pathway. Lower expression levels of this gene prevent APC binding to and eventual
phosphorylation/degradation of β-catenin, thereby permitting continued effector activity upon
nuclear translocation of β-catenin. Given that these were two of the strongest associations for
preferential gene under expression and given that we know that Wnt/β-catenin signaling is
deregulated in greater than 90% of colorectal cancers41, even in the absence of an APC
mutation, we were next interested in investigating whether or not non-APC genes may be
susceptible to the effects of epigenetic modulation in Wnt/β-catenin signaling via changes in
methylation.
For both xenograft models, AXIN2 was relatively over methylated in the untreated controls, and
methylation levels at the 5’-promoter and were significantly reversed from a hyper-methylated
state. This was also seen in other tumor suppressor genes imported in Wnt/β-catenin signaling
like APC2, FZD9, and LRP4. Corresponding gene expression profiling differences were noted
in FZD9 (25.7x) and APC 2 (4.02x) were noted with corresponding reversal in methylation by
azacitidine in both xenograft models. However, no statistically significant differences were noted
despite the high differential magnitude of these trends, which may have been statistically limited
by the low number of tumor specimens that were able to be assessed by this project. To
investigate further, we performed RT–PCR on RNA extracted from both control and
experimentally treated xenograft tumors to assess for any differences in gene expression using
a different methodology. Interestingly, RNF43 was preferentially increased in terms of gene
expression in the B1003 model that was exposed to azacitidine. Using a different model, an
HT29 BRAF–mutated colorectal cancers line, use of a deep bleeding agent was associated with
a decrease in methylation profile with corresponding trend towards increase in gene expression
for genes like AXIN2, FZD1, LRP4, and LRP5. Collectively, these findings may suggest that
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negative regulators important in Wnt/β-catenin signaling may be influenced by epigenetic
modifications in methylation, and have the potential to be targeted in the future.
The implications of these findings are important when translating towards clinical applications. A
recent phase II clinical trial assessing the addition of a porcupine inhibitor to agents against
BRAF and EGFR completed for patients with BRAF mutated metastatic colorectal cancer
harboring concomitant RNF 43 mutations. While current clinical trials often consider only
genomic aberrations (e.g., mutations) in determining inclusion criteria for assessing tumors with
a targetable drug against a known/defined aberrant signaling pathway, our data suggest that
non-genomic/epigenetic aberrations, and their corresponding influence on the pathogenesis of a
given tumor, should be considered as well when seeking to identify patients who may benefit
from a novel therapeutic agent under study. From our results, given that methylation can be
associated with potential gene expression, we support the idea that gene expression profiling
may better include patients with aberrant Wnt/β-catenin signaling of interest in future clinical
trials.
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Chapter V
LIMITATIONS
We did not see any antitumor response with the addition of a demethylating agent to treatment
with a BRAF inhibitor. However, since the time that this experimental design was planned,
preclinical work has shown that inhibition of BRAF in the BRAF–mutated colorectal cancer is
associated with an upregulation in EGFR, and that antitumor responses can be restored with
the addition of an anti-–EGFR therapy. Clinical trials that are currently ongoing will provide
additional insight into the efficacy of combined targeted therapies against both BRAF and
EGFR. Given this updated knowledge, the more clinically applicable experimental design would
have been to test the addition of azacitidine to therapies targeting both BRAF (vemurafenib) and
EGFR (cetuximab).
Although trends were seen in differential gene expression by both RT–PCR of RNA extracted
from xenograft models treated with azacitidine and from cell line models of BRAF mutated
colorectal cancer treated with azacitidine, no statistically significant differences were detected.
Given the finding that was available for this project from the ASCO Young Investigator Award,
we were able to perform analyses only on a few selected tumors. The trends that we observed
may have been limited by high standard deviations reflective of a low sample size. Increasing
the sample size and including additional tumor samples may have detected statistically a
difference back only be inferred at present with the current trends.
Formatted: Centered
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Chapter VI

Formatted: Font: Bold

FUTURE DIRECTIONS
We are collaborating with a company in the Texas Medical Center who has created a novel
inhibitor of Wnt/β-catenin signaling whose activity is very downstream in the nucleus. Given that
we have this increased understanding of the role of this pathway that it is important and BRAF
mutated colorectal cancer pathogenesis based on these data, we would like to test this in
combination with targeted therapies against both BRAF and EGFR in preclinical xenograft
models. If promising activity is observed, then we propose translating these findings into a
clinical trial.
We are also set to open a clinical trial at M.D. Anderson in the coming months which
incorporates an antibody against RSPO, another regulator important in signaling of the Wnt/βcatenin pathway, in combination with the cytotoxic chemotherapy regimen FOLFIRI. Inclusion
criteria for the study will build upon our conclusion here that patients must have high levels of
expression of RSPO in order to be candidates for the dose expansion portion of the study.
Therefore, gene expression profiling will be incorporated into the screening process.

32

REFERENCES
1.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for
clinicians. 2016;66(1):7-30.

2.

Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad
M, Blumgart LH, Brennan MF. Liver resection for colorectal metastases. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology.
1997;15(3):938-946.

3.

Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD,
Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection
for hepatic colorectal metastases. Annals of surgery. 2002;235(6):759-766.

4.

Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey
JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is
associated with adoption of hepatic resection and improved chemotherapy. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology.
2009;27(22):3677-3683.

5.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, CortesFunes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de
Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without
oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of clinical
oncology : official journal of the American Society of Clinical Oncology.
2000;18(16):2938-2947.

6.

Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, Seymour MT. A
'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced
colorectal cancer. British journal of cancer. 2002;87(4):393-399.

33

7.

Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Gilles V, Lotz JP,
Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M. Evaluation of oxaliplatin
dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion
regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology
Multidisciplinary Research Group (GERCOR). Annals of oncology : official journal of the
European Society for Medical Oncology / ESMO. 2000;11(11):1477-1483.

8.

Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V,
Krulik M, Carola E, Izrael V, de Gramont A. CPT-11 (irinotecan) addition to bimonthly,
high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for
pretreated metastatic colorectal cancer. GERCOR. European journal of cancer.
1999;35(9):1343-1347.

9.

Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G,
Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting
M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. The New England journal of medicine. 2009;360(14):14081417.

10.

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky
G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M,
Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III
trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)
versus FOLFOX4 alone as first-line treatment in patients with previously untreated
metastatic colorectal cancer: the PRIME study. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology. 2010;28(31):4697-4705.

11.

Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser
M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination with
oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a
34

randomized phase III study. Journal of clinical oncology : official journal of the American
Society of Clinical Oncology. 2008;26(12):2013-2019.
12.

Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R,
Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausova J, Garcia-Alfonso P,
Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F,
Investigators RS. Ramucirumab versus placebo in combination with second-line
FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after
first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a
randomised, double-blind, multicentre, phase 3 study. The Lancet. Oncology.
2015;16(5):499-508.

13.

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E,
Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E,
Tzekova V, Collins S, Oliner KS, Rong A, Gansert J. Randomized phase III study of
panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with
FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2010;28(31):4706-4713.

14.

Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki
A, Vamvakas L, Kotsakis A, Agelaki S, Diamandidou E, Touroutoglou N, Chatzidakis A,
Georgoulias V, Mavroudis D, Souglakos J. Front-line bevacizumab in combination with
oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal
cancer: a multicenter phase II study. BMC cancer. 2007;7:91.

15.

Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N.
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial,
including survival and subset analyses. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology. 2011;29(28):3768-3774.
35

16.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski
R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for
panitumumab efficacy in patients with metastatic colorectal cancer. Journal of clinical
oncology : official journal of the American Society of Clinical Oncology.
2008;26(10):1626-1634.

17.

Price TJ, Bruhn MA, Lee CK, Hardingham JE, Townsend AR, Mann KP, Simes J,
Weickhardt A, Wrin JW, Wilson K, Gebski V, Van Hazel G, Robinson B, Cunningham D,
Tebbutt NC. Correlation of extended RAS and PIK3CA gene mutation status with
outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in
combination with bevacizumab plus or minus mitomycin C in advanced colorectal
cancer. British journal of cancer. 2015;112(6):963-970.

18.

Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea
S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil,
leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of
metastatic colorectal cancer. Journal of clinical oncology : official journal of the American
Society of Clinical Oncology. 2009;27(5):663-671.

19.

Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi
B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile
JF, Penault-Llorca F, Laurent-Puig P. KRAS mutations as an independent prognostic
factor in patients with advanced colorectal cancer treated with cetuximab. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology.
2008;26(3):374-379.

20.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes
RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore
MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal
cancer. The New England journal of medicine. 2008;359(17):1757-1765.
36

21.

Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW,
Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, 3rd, Poplin
EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ. Expression of epiregulin and
amphiregulin and K-ras mutation status predict disease control in metastatic colorectal
cancer patients treated with cetuximab. Journal of clinical oncology : official journal of
the American Society of Clinical Oncology. 2007;25(22):3230-3237.

22.

Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. The New
England journal of medicine. 2009;361(1):98-99.

23.

Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk
S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD,
Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP,
Investigators MCT. Addition of cetuximab to oxaliplatin-based first-line combination
chemotherapy for treatment of advanced colorectal cancer: results of the randomised
phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103-2114.

24.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H,
Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R,
Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S,
Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, PritchardJones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A,
Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow
TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations
of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.

25.

Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM,
Marshall CJ, Springer CJ, Barford D, Marais R, Cancer Genome P. Mechanism of
activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell.
2004;116(6):855-867.
37

26.

Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H,
Tateishi K, Kawakami T, Aragaki J, Matsumura M, Kawabe T, Omata M. Functional
analysis of mutations within the kinase activation segment of B-Raf in human colorectal
tumors. Cancer research. 2003;63(23):8132-8137.

27.

Pritchard C, Carragher L, Aldridge V, Giblett S, Jin H, Foster C, Andreadi C, Kamata T.
Mouse models for BRAF-induced cancers. Biochem Soc Trans. 2007;35(Pt 5):13291333.

28.

Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer.
Oncogene. 2007;26(22):3279-3290.

29.

Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D,
Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over
sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.
Clinical colorectal cancer. 2014;13(3):164-171.

30.

Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O,
Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of
metastatic spread and prognosis in metastatic colorectal cancer. Cancer.
2011;117(20):4623-4632.

31.

Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A,
Shivasami A, Cummins MM, Murone C, Tebbutt NC. Impact of KRAS and BRAF Gene
Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine
Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal
Cancer. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology. 2011;29(19):2675-2682.

32.

Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK,
Slattery ML. Poor survival associated with the BRAF V600E mutation in microsatellitestable colon cancers. Cancer research. 2005;65(14):6063-6069.
38

33.

Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H,
Stathopoulos E, Georgoulias V, Souglakos J. BRAF mutations, microsatellite instability
status and cyclin D1 expression predict metastatic colorectal patients' outcome. British
journal of cancer. 2010;102(12):1762-1768.

34.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R,
Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D,
Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J,
Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, Group B-S. Improved survival with
vemurafenib in melanoma with BRAF V600E mutation. The New England journal of
medicine. 2011;364(26):2507-2516.

35.

Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA,
Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I,
Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB,
Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated
with vemurafenib. The New England journal of medicine. 2012;366(8):707-714.

36.

Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A,
Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L.
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated
Colorectal Cancer. Journal of clinical oncology : official journal of the American Society
of Clinical Oncology. 2015;33(34):4032-4038.

37.

Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O,
Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S,
Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK
Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015;33(34):4023-4031.
39

38.

Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della
Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, MinoKenudson M, Engelman JA. EGFR-mediated re-activation of MAPK signaling contributes
to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Cancer discovery. 2012;2(3):227-235.

39.

Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen
RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E)
inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100-103.

40.

Morris V. Circulating cell-free DNA as a marker for response and resistance to BRAF
and EGFR inhibition in BRAF-mutated metastatic colorectal cancer. Paper presented at:
AACR Molecular Targets2015.

41.

Cancer Genome Atlas N. Comprehensive molecular characterization of human colon
and rectal cancer. Nature. 2012;487(7407):330-337.

42.

Hendriks YM, de Jong AE, Morreau H, Tops CM, Vasen HF, Wijnen JT, Breuning MH,
Brocker-Vriends AH. Diagnostic approach and management of Lynch syndrome
(hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA: a cancer
journal for clinicians. 2006;56(4):213-225.

43.

Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ, Thibodeau
SN. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite
instability. Cancer research. 1998;58(15):3455-3460.

44.

Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH,
Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B,
Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW. CpG island
methylator phenotype underlies sporadic microsatellite instability and is tightly
associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787-793.

40

45.

Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S,
Konishi K, Hamilton SR, Issa JP. Integrated genetic and epigenetic analysis identifies
three different subclasses of colon cancer. Proceedings of the National Academy of
Sciences of the United States of America. 2007;104(47):18654-18659.

46.

Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins
genetics. Trends Genet. 2000;16(4):168-174.

47.

Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21(2):163-167.

48.

Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes
premature cell senescence associated with accumulation of p53 and p16INK4a. Cell.
1997;88(5):593-602.

49.

Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces
senescence and apoptosis through pathways mediated by the secreted protein IGFBP7.
Cell. 2008;132(3):363-374.

50.

Suzuki H, Igarashi S, Nojima M, Maruyama R, Yamamoto E, Kai M, Akashi H, Watanabe
Y, Yamamoto H, Sasaki Y, Itoh F, Imai K, Sugai T, Shen L, Issa JP, Shinomura Y,
Tokino T, Toyota M. IGFBP7 is a p53-responsive gene specifically silenced in colorectal
cancer with CpG island methylator phenotype. Carcinogenesis. 2010;31(3):342-349.

51.

Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui
WW, Chan AS, Futreal PA, Stratton MR, Wooster R, Leung SY. Similarity of the
phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
Cancer research. 2002;62(22):6451-6455.

52.

Chan TL, Zhao W, Leung SY, Yuen ST, Cancer Genome P. BRAF and KRAS mutations
in colorectal hyperplastic polyps and serrated adenomas. Cancer research.
2003;63(16):4878-4881.

53.

Miyaki M, Konishi M, Kikuchi-Yanoshita R, Enomoto M, Igari T, Tanaka K, Muraoka M,
Takahashi H, Amada Y, Fukayama M, et al. Characteristics of somatic mutation of the
41

adenomatous polyposis coli gene in colorectal tumors. Cancer research.
1994;54(11):3011-3020.
54.

Kahn M. Can we safely target the WNT pathway? Nature reviews. Drug discovery.
2014;13(7):513-532.

55.

Giannakis M, Hodis E, Jasmine Mu X, Yamauchi M, Rosenbluh J, Cibulskis K, Saksena
G, Lawrence MS, Qian ZR, Nishihara R, Van Allen EM, Hahn WC, Gabriel SB, Lander
ES, Getz G, Ogino S, Fuchs CS, Garraway LA. RNF43 is frequently mutated in
colorectal and endometrial cancers. Nat Genet. 2014;46(12):1264-1266.

56.

Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, van Es JH,
Mohammed S, Heck AJ, Maurice MM, Clevers H. Tumour suppressor RNF43 is a stemcell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012;488(7413):665669.

57.

Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S,
Guan Y, Janakiraman V, Jaiswal BS, Guillory J, Ha C, Dijkgraaf GJ, Stinson J, Gnad F,
Huntley MA, Degenhardt JD, Haverty PM, Bourgon R, Wang W, Koeppen H, Gentleman
R, Starr TK, Zhang Z, Largaespada DA, Wu TD, de Sauvage FJ. Recurrent R-spondin
fusions in colon cancer. Nature. 2012;488(7413):660-664.

58.

Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2000;103(2):311320.

59.

Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in
colorectal cancer. Nat Rev Cancer. 2001;1(1):55-67.

60.

Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev. 1999;9(1):1521.

61.

MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms,
and diseases. Dev Cell. 2009;17(1):9-26.

42

62.

Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng
D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, Phung V, Guo G,
Wang Y, Graham MP, Flynn S, Brenner JC, Li C, Villarroel MC, Schultz PG, Wu X,
McNamara P, Sellers WR, Petruzzelli L, Boral AL, Seidel HM, McLaughlin ME, Che J,
Carey TE, Vanasse G, Harris JL. Targeting Wnt-driven cancer through the inhibition of
Porcupine by LGK974. Proceedings of the National Academy of Sciences of the United
States of America. 2013;110(50):20224-20229.

63.

Taylor SM, Jones PA. Mechanism of action of eukaryotic DNA methyltransferase. Use of
5-azacytosine-containing DNA. J Mol Biol. 1982;162(3):679-692.

64.

Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty
R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D,
Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin
SB, Zahnow CA. Transient low doses of DNA-demethylating agents exert durable
antitumor effects on hematological and epithelial tumor cells. Cancer Cell.
2012;21(3):430-446.

65.

Sharp AJ, Stathaki E, Migliavacca E, Brahmachary M, Montgomery SB, Dupre Y,
Antonarakis SE. DNA methylation profiles of human active and inactive X chromosomes.
Genome Res. 2011;21(10):1592-1600.

66.

Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal
cancer. The New England journal of medicine. 2009;361(25):2449-2460.

43

VITA
Van Karlyle Morris II was born on July 26, 1980 in Memphis, Tennessee, the son of Van Karlyle
Morris and Tessa Ann Morris. After completing high school from Memphis University School in
May 1998, he entered the University of North Carolina at Chapel Hill. He graduated with a
Bachelor of Sciences degree in Chemistry with Highest Honors in May 2002. For two years, he
worked as a research technician in the Department of Structural Biology at St. Jude Children’s
Research Hospital in Memphis, Tennessee. In August 2004, he enrolled in medical school at
the University of Tennessee Health Sciences Center. Upon earning his Doctorate of Medicine
in May 2008, he then trained in Internal Medicine for residency at Duke University until June
2011. After residency, he completed his fellowship in Hematology/Oncology at the University of
Texas – MD Anderson Cancer Center in June 2014. Since that time, he has been a faculty
member at the MD Anderson in the Department of Gastrointestinal Medical Oncology, where he
is currently an Assistant Professor.

44

